Effect of Vitamin D (Cholecalciferol) supplementation on bone mineral metabolism in patient on Dialysis
Phase 4
- Conditions
- End stage renal disease patients on hemodialysis.End stage kidney disease:on dialysis
- Registration Number
- IRCT2015091323989N1
- Lead Sponsor
- ephrology Department, Shaikh Zayad Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Age more than 18 years
On hemodialysis thrice per week for more than 3 months
Both the gender
Patients who give informed consents
Exclusion criteria:
The patients with history of active bleeding (melena, hematemesis, hematochezia).
Patients who have taken cholecalceferol or ergocholicalciferol within two months period,
Patients taking cinacalcet
Iv Iron in 1 month prior to enrollment
Blood transfusion 1month prior to enrollment during the study
Any diagnosed malignancy, tubercular infection, sarcoidosis, pregnancy
Calcitriol or active vitamin D3 or erythropoietin dosage adjustment 1 month prior to enrollment
Patients having corrected serum calcium>10.2 mg/dl or having serum phosphorus >6mg/dl
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. 25 hydroxyvitamin D level. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA kit.;2. intact Parathyroid Hormone (iPTH). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA kit.;3. Alkaline Phosphatase. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;4. Calcium (Ca). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;5. Phosphorus (P). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;6. calcium phosphorus product(Ca x P). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: calculated from calcium and phosphorus product.
- Secondary Outcome Measures
Name Time Method 1. C Reactive Protein. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA Kit.;2. Chronic musculoskeletal symptoms. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Visual Analog Scale.;3. White blood cell count. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Automated counter.